Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: A meta-analysis

Xavier Paoletti; Koji Oba; Yung Jue Bang; Harry Bleiberg; Narikazu Boku; Olivier Bouché; Paul Catalano; Nozomu Fuse; Stefan Michiels; Markus Moehler; Satoshi Morita; Yasuo Ohashi; Atsushi Ohtsu; Arnaud Roth; Philippe Rougier; Junichi Sakamoto; Daniel Sargent; Mitsuru Sasako; Kohei Shitara; Peter Thuss-Patience; Eric Van Cutsem; Tomasz Burzykowski; Marc Buyse

doi:10.1093/jnci/djt269

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: A meta-analysis

Xavier Paoletti, Koji Oba, Yung Jue Bang, Harry Bleiberg, Narikazu Boku, Olivier Bouché, Paul Catalano, Nozomu Fuse, Stefan Michiels, Markus Moehler, Satoshi Morita, Yasuo Ohashi, Atsushi Ohtsu, Arnaud Roth, Philippe Rougier, Junichi Sakamoto, Daniel Sargent, Mitsuru Sasako, Kohei Shitara, Peter Thuss-PatienceEric Van Cutsem, Tomasz Burzykowski, Marc Buyse

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

72 Citations (Scopus)

Résumé

The traditional endpoint for assessing efficacy of chemotherapies for advanced/ recurrent gastric cancer is overall survival (OS), but OS requires prolonged follow-up. We investigated whether progression-free survival (PFS) is a valid surrogate for OS. Using individual patient data from the GASTRIC meta-analysis, surrogacy of PFS was assessed through the correlation between the endpoints and through the correlation between the treatment effects on the endpoints. External validation of the prediction based on PFS was also evaluated. Individual data from 4069 patients in 20 randomized trials were analyzed. The rank correlation coefficient between PFS and OS was 0.853 (95% confidence interval [CI] = 0.852 to 0.854). The R2 between treatment effects on PFS and on OS was 0.61 (95% CI = 0.04 to 1.00). Treatment effects on PFS and on OS were only moderately correlated, and we could not confirm the validity of PFS as a surrogate endpoint for OS in advanced/recurrent gastric cancer.

langue originale	Anglais
Pages (de - à)	1667-1670
Nombre de pages	4
journal	Journal of the National Cancer Institute
Volume	105
Numéro de publication	21
Les DOIs	https://doi.org/10.1093/jnci/djt269
état	Publié - 6 nov. 2013

Accès au document

10.1093/jnci/djt269

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Paoletti, X., Oba, K., Bang, Y. J., Bleiberg, H., Boku, N., Bouché, O., Catalano, P., Fuse, N., Michiels, S., Moehler, M., Morita, S., Ohashi, Y., Ohtsu, A., Roth, A., Rougier, P., Sakamoto, J., Sargent, D., Sasako, M., Shitara, K., ... Buyse, M. (2013). Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: A meta-analysis. Journal of the National Cancer Institute, 105(21), 1667-1670. https://doi.org/10.1093/jnci/djt269

@article{706c4e57e9104ecfa1fb396c7eaa8bb4,

title = "Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: A meta-analysis",

abstract = "The traditional endpoint for assessing efficacy of chemotherapies for advanced/ recurrent gastric cancer is overall survival (OS), but OS requires prolonged follow-up. We investigated whether progression-free survival (PFS) is a valid surrogate for OS. Using individual patient data from the GASTRIC meta-analysis, surrogacy of PFS was assessed through the correlation between the endpoints and through the correlation between the treatment effects on the endpoints. External validation of the prediction based on PFS was also evaluated. Individual data from 4069 patients in 20 randomized trials were analyzed. The rank correlation coefficient between PFS and OS was 0.853 (95% confidence interval [CI] = 0.852 to 0.854). The R2 between treatment effects on PFS and on OS was 0.61 (95% CI = 0.04 to 1.00). Treatment effects on PFS and on OS were only moderately correlated, and we could not confirm the validity of PFS as a surrogate endpoint for OS in advanced/recurrent gastric cancer.",

author = "Xavier Paoletti and Koji Oba and Bang, {Yung Jue} and Harry Bleiberg and Narikazu Boku and Olivier Bouch{\'e} and Paul Catalano and Nozomu Fuse and Stefan Michiels and Markus Moehler and Satoshi Morita and Yasuo Ohashi and Atsushi Ohtsu and Arnaud Roth and Philippe Rougier and Junichi Sakamoto and Daniel Sargent and Mitsuru Sasako and Kohei Shitara and Peter Thuss-Patience and {Van Cutsem}, Eric and Tomasz Burzykowski and Marc Buyse",

year = "2013",

month = nov,

day = "6",

doi = "10.1093/jnci/djt269",

language = "English",

volume = "105",

pages = "1667--1670",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

number = "21",

}

Paoletti, X, Oba, K, Bang, YJ, Bleiberg, H, Boku, N, Bouché, O, Catalano, P, Fuse, N, Michiels, S, Moehler, M, Morita, S, Ohashi, Y, Ohtsu, A, Roth, A, Rougier, P, Sakamoto, J, Sargent, D, Sasako, M, Shitara, K, Thuss-Patience, P, Van Cutsem, E, Burzykowski, T & Buyse, M 2013, 'Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: A meta-analysis', Journal of the National Cancer Institute, VOL. 105, Numéro 21, p. 1667-1670. https://doi.org/10.1093/jnci/djt269

TY - JOUR

T1 - Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials

T2 - A meta-analysis

AU - Paoletti, Xavier

AU - Oba, Koji

AU - Bang, Yung Jue

AU - Bleiberg, Harry

AU - Boku, Narikazu

AU - Bouché, Olivier

AU - Catalano, Paul

AU - Fuse, Nozomu

AU - Michiels, Stefan

AU - Moehler, Markus

AU - Morita, Satoshi

AU - Ohashi, Yasuo

AU - Ohtsu, Atsushi

AU - Roth, Arnaud

AU - Rougier, Philippe

AU - Sakamoto, Junichi

AU - Sargent, Daniel

AU - Sasako, Mitsuru

AU - Shitara, Kohei

AU - Thuss-Patience, Peter

AU - Van Cutsem, Eric

AU - Burzykowski, Tomasz

AU - Buyse, Marc

PY - 2013/11/6

Y1 - 2013/11/6

N2 - The traditional endpoint for assessing efficacy of chemotherapies for advanced/ recurrent gastric cancer is overall survival (OS), but OS requires prolonged follow-up. We investigated whether progression-free survival (PFS) is a valid surrogate for OS. Using individual patient data from the GASTRIC meta-analysis, surrogacy of PFS was assessed through the correlation between the endpoints and through the correlation between the treatment effects on the endpoints. External validation of the prediction based on PFS was also evaluated. Individual data from 4069 patients in 20 randomized trials were analyzed. The rank correlation coefficient between PFS and OS was 0.853 (95% confidence interval [CI] = 0.852 to 0.854). The R2 between treatment effects on PFS and on OS was 0.61 (95% CI = 0.04 to 1.00). Treatment effects on PFS and on OS were only moderately correlated, and we could not confirm the validity of PFS as a surrogate endpoint for OS in advanced/recurrent gastric cancer.

AB - The traditional endpoint for assessing efficacy of chemotherapies for advanced/ recurrent gastric cancer is overall survival (OS), but OS requires prolonged follow-up. We investigated whether progression-free survival (PFS) is a valid surrogate for OS. Using individual patient data from the GASTRIC meta-analysis, surrogacy of PFS was assessed through the correlation between the endpoints and through the correlation between the treatment effects on the endpoints. External validation of the prediction based on PFS was also evaluated. Individual data from 4069 patients in 20 randomized trials were analyzed. The rank correlation coefficient between PFS and OS was 0.853 (95% confidence interval [CI] = 0.852 to 0.854). The R2 between treatment effects on PFS and on OS was 0.61 (95% CI = 0.04 to 1.00). Treatment effects on PFS and on OS were only moderately correlated, and we could not confirm the validity of PFS as a surrogate endpoint for OS in advanced/recurrent gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=84890486267&partnerID=8YFLogxK

U2 - 10.1093/jnci/djt269

DO - 10.1093/jnci/djt269

M3 - Article

C2 - 24108811

AN - SCOPUS:84890486267

SN - 0027-8874

VL - 105

SP - 1667

EP - 1670

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 21

ER -